1Rosing J, Hemker H C, Tans G. Molecular biology and pathophysiology of APC resistance: current insights and clinical im placations [J]. Scm in Throm b-Hemost, 1998,24(4):329.
2Lidegaard O, Bygdeman M, Molsom L, et al. Oral contraceptives and throm bosis: From risk estimates to health impact[J]. Acta Obstet GynecolScand, 1999,78(2): 142.
3Sidney S, Siscovick D S, Petiti D B, et al. Oral contraceptives and myocardial infarction [J]. Circulation, 1998,98(11):1058-1063.
4Heinemann L A J, Lewis M A, Spitzer W O, et al. Oral contraceptives and cerebral stroke[J]. Contraception, 1998, 57(1):29-37.
5Dawn M, Grabrick M P H, Lynn C, et al. Risk of Breast Cancer With Oral Contraceptive [J]. Use in Women With a Family History of Breast Cancer, 2001,20(3):140.
6Thomeycroft I H.Evolution of progestins:Focus on the novel progestin drospirenone[J].J Reprod Med,2002,47(11 Suppl):975-984.
7Kulier R,Helmerhorst F M,MalWa N.et al.Effectiveness and acceptability of progestogens in combined oral contraceptives-a systematic review[J].Reprod Health,2004,1(1):1.
8Novotua M,Huvar I,BIalla O.Long-term use of combined hormonal contraception-myths and reality[J].Ceska Gynekol,2002,67(5):297-304.
9Bassol S,Alvarado G,Arreola R G,et al.A 13-month multicenter clinical experience of a low-dose monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene in Latin American women[J].Contraception,2003,67(5):367-372.
10Poindexter A.The emerging use of the 20-micmg oral contraceptive[J].Fertil Steril,2001,75(3)457-465.
6Goldzieher JW. Newer drugs in oral contraception[ J]. Med Clin No- i rth Am,1964, 48(3) :529 -545.
7Liedman R, Hansson SR, Howe D, et al. Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea cOmpared ~ I with healthy subjects [ J ]. Gyneco| Endoennol, 2008,24 ( 9 ) i 508 - 513.
8Williams JK. Contraceptive needs of the perlmenopausal woman [ J ]. Obstet Gynecol Clin North Am,2002,29 (3) :575 -588.
